Highlight
This multicentric, double-blind, phase III trial from India establishes that elagolix provides non-inferior pain relief compared to dienogest in women suffering from moderate-to-severe endometriosis-associated pain. Both treatments led to significant reductions in various pain domains, with comparable safety profiles and no adverse impact on bone mineral density over 24 weeks.
